UBS Group AG - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 166 filers reported holding REVANCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,353,976
-58.9%
118,045
-9.2%
0.00%
-100.0%
Q2 2023$3,290,932
-51.6%
130,025
-38.5%
0.00%
-66.7%
Q1 2023$6,805,619
+4.5%
211,289
-40.1%
0.00%0.0%
Q4 2022$6,513,150
+191.5%
352,825
+326.3%
0.00%
+200.0%
Q3 2022$2,234,000
+86.0%
82,762
-4.8%
0.00%
Q2 2022$1,201,000
-31.0%
86,909
-2.6%
0.00%
-100.0%
Q1 2022$1,741,000
+26.1%
89,270
+5.5%
0.00%
Q4 2021$1,381,000
-19.1%
84,655
+38.1%
0.00%
-100.0%
Q3 2021$1,707,000
+8.3%
61,281
+15.2%
0.00%0.0%
Q2 2021$1,576,000
+4.2%
53,182
-1.8%
0.00%0.0%
Q1 2021$1,513,000
+11.2%
54,134
+12.8%
0.00%
Q4 2020$1,360,000
+11.6%
47,994
-1.1%
0.00%
Q3 2020$1,219,000
-6.1%
48,505
-8.7%
0.00%
-100.0%
Q2 2020$1,298,000
+115.3%
53,153
+30.5%
0.00%
Q1 2020$603,000
-43.4%
40,726
-38.0%
0.00%
Q4 2019$1,065,000
+5816.7%
65,650
+4589.3%
0.00%
Q3 2019$18,0000.0%1,4000.0%0.00%
Q2 2019$18,000
-5.3%
1,400
+15.1%
0.00%
Q1 2019$19,000
+111.1%
1,216
+171.4%
0.00%
Q4 2018$9,000
-82.7%
448
-78.3%
0.00%
Q3 2018$52,000
-45.3%
2,065
-40.1%
0.00%
Q2 2018$95,000
+18.8%
3,448
+32.9%
0.00%
Q1 2018$80,000
-5.9%
2,594
+9.0%
0.00%
Q4 2017$85,000
+32.8%
2,380
+2.0%
0.00%
Q3 2017$64,000
+392.3%
2,334
+356.8%
0.00%
Q2 2017$13,000511
+4545.5%
0.00%
Q1 2017$0
-100.0%
11
-99.0%
0.00%
Q4 2016$22,000
-29.0%
1,052
-44.5%
0.00%
Q3 2016$31,000
+342.9%
1,896
+271.0%
0.00%
Q2 2016$7,000
-22.2%
5110.0%0.00%
Q1 2016$9,000
-85.9%
511
-72.9%
0.00%
Q4 2015$64,000
+326.7%
1,889
+277.8%
0.00%
Q3 2015$15,000
-6.2%
5000.0%0.00%
Q2 2015$16,000
+23.1%
500
-23.9%
0.00%
Q1 2015$13,000
-40.9%
657
-49.7%
0.00%
Q4 2014$22,0001,3050.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
NovaQuest Capital Management, L.L.C. 1,558,426$48,000,00065.50%
Essex Woodlands Management, Inc. 3,842,047$118,335,00025.90%
Rhenman & Partners Asset Management AB 203,181$6,258,0000.77%
EAM Global Investors LLC 44,898$1,383,0000.72%
Fosun International Ltd 319,313$9,835,0000.62%
EAM Investors, LLC 113,096$3,483,0000.58%
ArrowMark Colorado Holdings LLC 1,735,699$53,460,0000.53%
Perceptive Advisors 618,957$19,064,0000.53%
ESSEX INVESTMENT MANAGEMENT CO LLC 111,360$3,430,0000.45%
Schonfeld Strategic Advisors LLC 83,700$2,578,0000.19%
View complete list of REVANCE THERAPEUTICS INC shareholders